Guidelines For Insulin Initiation and Adjustment In Primary Care

More documents

Recommendations

Info

Appendix 3 Guidelines For Insulin Adjustment In Primary Care Scottish Medicines Consortium insulin detemir (Levemir Ò) No. 110/04 Novo Nordisk Summary of Advice 9 August 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows: Advice: following a full submission. Insulin detemir is accepted for restricted use within NHS Scotland for the treatment of diabetes mellitus. Insulin detemir is an acceptable basal insulin for patients with diabetes mellitus. Its use should be targeted on patients attempting to achieve better hypoglycaemic control as there may be some benefit related to a reduced intra-individual variation in glycaemic profile for insulin detemir compared with established insulins. It appears to be cost- effective from the base-case of economic modelling, but this is limited by the degree of extrapolation involved and the associated width of the confidence intervals. Professor David H Lawson Chairman Reviewed January 2010 29
Appendix 3 Guidelines For Insulin Adjustment In Primary Care Scottish Medicines Consortium insulin detemir, 100 U/ml solution for injection via InnoLet® device (Levemir® in InnoLet®) No. (393/07) Novo Nordisk Ltd Product Update 6 July 2007 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission insulin detemir (Levemir®) for injection via the InnoLet® device is accepted for restricted use within NHS Scotland for treatment of diabetes mellitus in patients for whom insulin detemir is an appropriate choice of insulin and who have poor visual acuity and dexterity problems. The Scottish Medicines Consortium has previously advised that insulin detemir should be restricted to patients attempting to achieve better hypoglycaemic control as there may be some benefit related to a reduced intra-individual variation in glycaemic profile for insulin detemir compared with established insulins. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. This assessment is based on data submitted by the applicant company up to and including 14 June 2007. Chairman, Scottish Medicines Consortium Reviewed January 2010 30
Page 1 and 2: Guidelines for Insulin Initiation a
Page 3 and 4: Table of Contents Guidelines For In
Page 5 and 6: Guidelines For Insulin Adjustment I
Page 7 and 8: Table A Guidelines For Insulin Adju
Page 17 and 18: INSULIN CONVERSION / EDUCATION CHEC
Page 27 and 28: Appendix 1 Guidelines For Insulin A
Page 29: Appendix 2 Guidelines For Insulin A
Page 35 and 36: Eli Lilly; www.lilly.co.uk 01256 31
Page 37: References: Reviewed January 2010 G

Guidelines For Insulin Initiation and Adjustment In Primary Care

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?